Literature DB >> 27458062

Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?

Giorgio Ivan Russo1, Sebastiano Cimino2, Tommaso Castelli2, Vincenzo Favilla2, Mauro Gacci3, Marco Carini3, Rosita A Condorelli4, Sandro La Vignera4, Aldo E Calogero4, Fabio Motta5, Lidia Puzzo5, Rosario Caltabiano5, Giuseppe Morgia2.   

Abstract

PURPOSE: The prevalence of prostatic inflammation (PI) is very frequent in patients affected by benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). To investigate the relationship between prostatic inflammation (PI) and the presence of MetS and non-alcoholic fatty liver disease (NAFLD) in a cohort of patients affected by BPH/LUTS.
METHODS: We conducted a prospective study from January 2012 to June 2014 on 264 consecutive patients, who underwent transurethral resection of the prostate for bladder outlet obstruction. Metabolic syndrome (MetS) has been defined according to the International Diabetes Federation (IDF). Prior to surgery, each patient has been evaluated for the presence of MetS and NAFLD. All surgical specimens were investigated for the presence of an inflammatory infiltrate, according to the Irani score.
RESULTS: The prevalence of patients affected by MetS alone was 13.8% (32/232), 13.8% (32/232) by NAFLD alone, and 42.7% (99/232) by both diseases. The rate of subjects affected by MetS + NAFLD and severe PI was significantly greater than those with only one metabolic alteration (75.8% vs. 24.2%, P < 0.01). The multivariate logistic regression analysis revealed that FLI was independently associated with high PI (Irani score ≥ 4) (odds ratio [OR]: 1.04; P < 0.01). Further, the combination between MetS and NAFLD was associated severe PI (OR: 4.5; P < 0.01) while not MetS as a single alteration.
CONCLUSIONS: Patients with BPH/LUTS and metabolic aberration exhibited grater PI. The coexistence of MetS and NAFLD exerted a greater detrimental effect on prostate gland by increasing severity of inflammation. Prostate 76:1528-1535, 2016.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  LUTS; benign prostatic hyperplasia; inflammation; metabolic syndrome; non-alcholic fatty liver disease; prostate

Mesh:

Year:  2016        PMID: 27458062     DOI: 10.1002/pros.23237

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm.

Authors:  Shuang Pan; Wandong Hong; Wenzhi Wu; Qinfen Chen; Qian Zhao; Jiansheng Wu; Yin Jin
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

2.  Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals.

Authors:  Zhenyu Ou; Yao He; Lin Qi; Xiongbin Zu; Longxiang Wu; Zhenzhen Cao; Yuan Li; Longfei Liu; Daud Athanasius Dube; Zhi Wang; Long Wang
Journal:  Oncotarget       Date:  2017-07-22

3.  The Combined Effect of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome on Osteoporosis in Postmenopausal Females in Eastern China.

Authors:  Da-Zhi Chen; Qiao-Mai Xu; Xiao-Xin Wu; Chao Cai; Ling-Jian Zhang; Ke-Qing Shi; Hong-Ying Shi; Lan-Juan Li
Journal:  Int J Endocrinol       Date:  2018-07-29       Impact factor: 3.257

4.  The combined effect of non-alcoholic fatty liver disease and metabolic syndrome on colorectal carcinoma mortality: a retrospective in Chinese females.

Authors:  Zhou-Feng Chen; Xiu-Li Dong; Qing-Ke Huang; Wang-Dong Hong; Wen-Zhi Wu; Jian-Sheng Wu; Shuang Pan
Journal:  World J Surg Oncol       Date:  2018-08-10       Impact factor: 2.754

5.  Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.

Authors:  Yoon Jin Choi; Dong Ho Lee; Kyung-Do Han; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

Review 6.  PCAF fine-tunes hepatic metabolic syndrome, inflammatory disease, and cancer.

Authors:  Tongxin Wang; Weilei Yao; Yafei Shao; Ruilong Zheng; Feiruo Huang
Journal:  J Cell Mol Med       Date:  2018-09-14       Impact factor: 5.310

7.  Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min Sun Kwak; Jong In Yang; Boram Park; Seong Joon An; Joo Sung Kim
Journal:  J Korean Med Sci       Date:  2020-06-08       Impact factor: 2.153

Review 8.  The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review.

Authors:  Giorgio Ivan Russo; Gaetano Larganà; Arcangelo Sebastianelli; Andrea Cocci; Marina Di Mauro; Ilenia Rapallo; Giuseppe Morgia; Matteo Mario Morgia; Sandro La Vignera; Rosita Condorelli; Aldo E Calogero; Iacopo Olivotto; Simone Morselli; Sergio Serni; Mauro Gacci
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

9.  Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.

Authors:  Bo Zhang; Xiang Chen; Yu-Hang Liu; Yu Gan; Pei-Hua Liu; Zhi Chen; Wei-Ping Xia; Guo-Yu Dai; Feng Ru; Ze-Xiang Jiang; Yao He
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

Review 10.  Endocrinology of the Aging Prostate: Current Concepts.

Authors:  Rossella Cannarella; Rosita A Condorelli; Federica Barbagallo; Sandro La Vignera; Aldo E Calogero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.